Understanding the drug resistance mechanism of hepatitis C virus NS3/4A to ITMN-191 due to R155K, A156V, D168A/E mutations: A computational study

Biochimica et Biophysica Acta - General Subjects

Volumn 1820, Issue 10, 2012, Pages 1526-1534

  Pan, Dabo ^a   Xue, Weiwei ^b   Zhang, Wenqi ^a   Liu, Huanxiang ^a   Yao, Xiaojun ^a,b  

^a LANZHOU UNIVERSITY   (China)

^b LANZHOU UNIVERSITY   (China)

Author keywords

Drug resistance; Hepatitis C virus; ITMN 191; Molecular dynamics simulation; NS3 4A protease

Indexed keywords

DANOPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; BINDING AFFINITY; CHEMICAL BOND; CONTROLLED STUDY; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENERGY METABOLISM; GENE MUTATION; HEPATITIS C VIRUS; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN CONFORMATION; WILD TYPE;

ALANINE; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; ARGININE; ASPARTIC ACID; COMPREHENSION; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; GLUTAMIC ACID; HEPACIVIRUS; LACTAMS; LYSINE; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MUTATION, MISSENSE; SULFONAMIDES; VALINE; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84863438978     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2012.06.001     Document Type: Article

References (45)

1. World Health Organization Media centre Hepatitis C Fact sheet N°164 http://www.who.int/mediacentre/factsheets/fs164/en/ 2011
2. D. Moradpour, F. Penin, and C.M. Rice Replication of hepatitis C virus Nat. Rev. Microbiol. 5 2007 453 463
3. Q.L. Choo, G. Kuo, A.J. Weiner, L.R. Overby, D.W. Bradley, and M. Houghton Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 1989 359 362
4. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, R. Reindollar, Z.D. Goodman, K. Koury, M. Ling, and J.K. Albrecht Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
5. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, F.L. Goncales Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N. Engl. J. Med. 347 2002 975 982
6. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, T.J. Urban, E.L. Heinzen, P. Qiu, A.H. Bertelsen, A.J. Muir, M. Sulkowski, J.G. McHutchison, and D.B. Goldstein Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
7. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M.L. Abate, M. Bassendine, U. Spengler, G.J. Dore, E. Powell, S. Riordan, D. Sheridan, A. Smedile, V. Fragomeli, T. Muller, M. Bahlo, G.J. Stewart, D.R. Booth, and J. George IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat. Genet. 41 2009 1100 1104
8. C.L. Murray, and C.M. Rice Hepatitis C: an unsuspected drug target Nature 465 2010 42 44
9. A.A. Kolykhalov, K. Mihalik, S.M. Feinstone, and C.M. Rice Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo J. Virol. 74 2000 2046 2051
10. J.M. Pawlotsky, and R.G. Gish Future therapies for hepatitis C Antivir. Ther. 11 2006 397 408
11. B. Wolk, D. Sansonno, H.G. Krausslich, F. Dammacco, C.M. Rice, H.E. Blum, and D. Moradpour Subcellular localization, stability, and trans-cleavage competence of he hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines J. Virol. 74 2000 2293 2304
12. K.E. Reed, A.E. Gorbalenya, and C.M. Rice The NS5A/NS5 proteins of viruses from three genera of the family flaviviridae are phosphorylated by associated serine/threonine kinases J. Virol. 72 1998 6199 6206
13. J.M. Lyle, E. Bullitt, K. Bienz, and K. Kirkegaard Visualization and functional analysis of RNA-dependent RNA polymerase lattices Science 296 2002 2218 2222
14. N. Yao, P. Reichert, S.S. Taremi, W.W. Prosise, and P.C. Weber Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase Structure 7 1999 1353 1363
15. K. Li, E. Foy, J.C. Ferreon, M. Nakamura, A.C. Ferreon, M. Ikeda, S.C. Ray, M. Gale Jr., and S.M. Lemon Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF Proc. Natl. Acad. Sci. U. S. A. 102 2005 2992 2997
16. E. Meylan, J. Curran, K. Hofmann, D. Moradpour, M. Binder, R. Bartenschlager, and J. Tschopp Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus Nature 437 2005 1167 1172
17. D. Lamarre, P.C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D.R. Cameron, M. Cartier, M.G. Cordingley, A.M. Faucher, N. Goudreau, S.H. Kawai, G. Kukolj, L. Lagace, S.R. LaPlante, H. Narjes, M.A. Poupart, J. Rancourt, R.E. Sentjens, R. St George, B. Simoneau, G. Steinmann, D. Thibeault, Y.S. Tsantrizos, S.M. Weldon, C.L. Yong, and M. Llinas-Brunet An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 426 2003 186 189
18. A. Franciscus Hepatitis C Treatments in Current Clinical Development 2011 (in)
19. M. Deutsch, and G.V. Papatheodoridis Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection Curr. Opin. Invest. Drugs 11 2010 951 963
20. S.D. Seiwert, S.W. Andrews, Y. Jiang, V. Serebryany, H. Tan, K. Kossen, P.T. Rajagopalan, S. Misialek, S.K. Stevens, A. Stoycheva, J. Hong, S.R. Lim, X. Qin, R. Rieger, K.R. Condroski, H. Zhang, M.G. Do, C. Lemieux, G.P. Hingorani, D.P. Hartley, J.A. Josey, L. Pan, L. Beigelman, and L.M. Blatt Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227) Antimicrob. Agents Chemother. 52 2008 4432 4441
21. M.P. Manns, G.R. Foster, J.K. Rockstroh, S. Zeuzem, F. Zoulim, and M. Houghton The way forward in HCV treatment - finding the right path Nat. Rev. Drug Discovery 6 2007 991 1000
22. C. Sarrazin, T.L. Kieffer, D. Bartels, B. Hanzelka, U. Muh, M. Welker, D. Wincheringer, Y. Zhou, H.M. Chu, C. Lin, C. Weegink, H. Reesink, S. Zeuzem, and A.D. Kwong Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 2007 1767 1777
23. H. Tan, S. Seiwert, and L. Blatt In vitro synergistic antiviral activity of ITMN-191, an orally active inhibitor of the hepatitis C virus (HCV) NS3/4A protease, in combination with Peg-Interferon alfa-2a Hepatology 44 2006 534A
24. S. Seiwert, S. Andrews, H. Tan, K. Condroski, J. Ballard, B. Bernat, J. Josey, and L. Blatt Generation and characterization of HCV replicons with reduced sensitivity to ITMN 191, a macrocyclic inhibitor of NS3/4A Gastroenterology 130 2006
25. K.P. Romano, A. Ali, W.E. Royer, and C.A. Schiffer Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding Proc. Natl. Acad. Sci. U. S. A. 107 2010 20986
26. O. Lenz, T. Verbinnen, T.I. Lin, L. Vijgen, M.D. Cummings, J. Lindberg, J.M. Berke, P. Dehertogh, E. Fransen, A. Scholliers, K. Vermeiren, T. Ivens, P. Raboisson, M. Edlund, S. Storm, L. Vrang, H. de Kock, G.C. Fanning, and K.A. Simmen In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435 Antimicrob. Agents Chemother. 54 2010 1878 1887
27. R. Rajagopalan, S. Misialek, S.K. Stevens, D.G. Myszka, B.J. Brandhuber, J.A. Ballard, S.W. Andrews, S.D. Seiwert, and K. Kossen Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior Biochemistry 48 2009 2559 2568
28. H. Liu, X. Yao, C. Wang, and J. Han In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase Mol. Pharm. 7 2010 894 904
29. T. Hou, J. Wang, Y. Li, and W. Wang Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations J. Chem. Inf. Model. 51 2011 69 82
30. T. Hou, and R. Yu Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance J. Med. Chem. 50 2007 1177 1188
31. D.S. Vieira, L. Degreve, and R.J. Ward Characterization of temperature dependent and substrate-binding cleft movements in Bacillus circulans family 11 xylanase: a molecular dynamics investigation Biochim. Biophys. Acta 1790 2009 1301 1306
32. W.L. DeLano The PyMOL Molecular Graphics System 2002 DeLano Scientific Palo Alto, CA, USA (in http://www.pymol.org., 2002)
33. M. Frisch, G. Trucks, H. Schlegel, G. Scuseria, M. Robb, J. Cheeseman, V. Zakrzewski, J. Montgomery Jr., R. Stratmann, and J. Burant Gaussian 98, Revision A. 9 1998 Gaussian Inc. Pittsburgh, PA
34. J. Wang, R.M. Wolf, J.W. Caldwell, P.A. Kollman, and D.A. Case Development and testing of a general amber force field J. Comput. Chem. 25 2004 1157 1174
35. Y. Duan, C. Wu, S. Chowdhury, M.C. Lee, G. Xiong, W. Zhang, R. Yang, P. Cieplak, R. Luo, T. Lee, J. Caldwell, J. Wang, and P. Kollman A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations J. Comput. Chem. 24 2003 1999 2012
36. M.C. Lee, and Y. Duan Distinguish protein decoys by using a scoring function based on a new AMBER force field, short molecular dynamics simulations, and the generalized born solvent model Proteins 55 2004 620 634
37. W.L. Jorgensen, J. Chandrasekhar, J.D. Madura, R.W. Impey, and M.L. Klein Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 79 1983 926 935
38. D.A. Case, T.E. Cheatham III, T. Darden, H. Gohlke, R. Luo, K.M. Merz Jr., A. Onufriev, C. Simmerling, B. Wang, and R.J. Woods The Amber biomolecular simulation programs J. Comput. Chem. 26 2005 1668 1688
39. U. Essmann, L. Perera, M.L. Berkowitz, T. Darden, H. Lee, and L.G. Pedersen A smooth particle mesh Ewald method J. Chem. Phys. 103 1995 8577 8593
40. J.-P. Ryckaert, G. Ciccotti, and H.J.C. Berendsen Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes J. Comput. Phys. 23 1977 327 341
41. P.A. Kollman, I. Massova, C. Reyes, B. Kuhn, S. Huo, L. Chong, M. Lee, T. Lee, Y. Duan, W. Wang, O. Donini, P. Cieplak, J. Srinivasan, D.A. Case, and T.E. Cheatham III Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models Acc. Chem. Res. 33 2000 889 897
42. J. Srinivasan, T.E. Cheatham, P. Cieplak, P.A. Kollman, and D.A. Case Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices J. Am. Chem. Soc. 120 1998 9401 9409
43. D. Sitkoff, K.A. Sharp, and B. Honig Accurate calculation of hydration free energies using macroscopic solvent models J. Phys. Chem. 98 1994 1978 1988
44. G. Rastelli, A. Del Rio, G. Degliesposti, and M. Sgobba Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA J. Comput. Chem. 31 2010 797 810
45. M.D. Cummings, J. Lindberg, T.I. Lin, H. de Kock, O. Lenz, E. Lilja, S. Fellander, V. Baraznenok, S. Nystrom, M. Nilsson, L. Vrang, M. Edlund, A. Rosenquist, B. Samuelsson, P. Raboisson, and K. Simmen Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target Angew. Chem. Int. Ed. Engl. 49 2010 1652 1655